Marzia Del Re works as Associate Professor at the Department of Faculty Medicine, Saint Camillus International University of Health and Medical Sciences (Rome, Italy) and at the Fondazione Policlinico A. Gemelli IRCCS (Rome, Italy).

Her research program is focused on the 1) diagnosis of adverse drug reactions by pharmacogenetic analysis of germline DNA and 2) monitoring of acquired resistance to targeted therapies using circulating nucleic acids released from tumors in plasma.

Prof. Del Re received her Pharm.D. degree in 2009 and became Specialist in Clinical Biochemistry in 2014 at the University of Pisa. She obtained the Master degree in “Clinical trials in Oncology, Hematology and Internal Medicine” in 2015 and the PhD title of Clinical Pathophysiology in 2018 at the University of Pisa.

Prof. Del Re received the Merit Awards from the American Society of Clinical Oncology (2011 and 2013) for her studies on DPYD variants and adverse drug reactions by fluoropyrimidines, which became in 2018 national recommendations for cancer patients candidate to fluoropyrimidines treatment. Prof. Del Re received many others awards for her studies on pharmacogenetics.

Prof. Del Re is member of national scientific society panels (AIOM, SIF) for clinical recommendations and guidelines, including the use of pharmacogenetic tests in cancer patients (DPD, UGT), liquid biopsy in clinical practice, and many others.

In 2015, 2016, 2018 and 2019 Prof. Del Re worked at the Erasmus Medical Center, Rotterdam (Netherlands) as Visiting scientist, on projects revolving around drug resistance in prostate and lung cancer and liquid biopsy. In 2017 Prof. Del Re worked at the NCI/NIH (Bethesda, USA) as Visiting Scientist, on in vitro prostate cancer models and drug resistance.

From 2018 to 2022 Prof. Del Re worked as employee at the Azienda Ospedaliero Universitaria in Pisa and from 2022 to 2024 worked as Assistant professor at the University of Pisa (Pisa, Italy).

From November 2022 Prof. Del Re worked as a Visiting Professor at the Center for Thoracic Oncology, The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai Hospital, working on liquid biopsy in lung cancer. In August 2023 Prof. Del Re worked at the Early Drug Development Service at the Merial Sloan Kettering Cancer Center to investigate mechanisms of resistance to new targeted therapies.